Cisplatin: mode of cytotoxic action and molecular basis of resistance
暂无分享,去创建一个
[1] P. O'Connor,et al. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard , 1997, Oncogene.
[2] A. V. D. Van Der Zee,et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.
[3] D. K. Treiber,et al. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.
[4] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[5] I. Roninson,et al. Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.
[6] S. Howell,et al. Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.
[7] S. Jackson,et al. Regulation of p53 in response to DNA damage , 1999, Oncogene.
[8] R. Ozols,et al. High Dose Cisplatin and Drug Resistance: Clinical and Laboratory Correlations , 1988 .
[9] J. Yu,et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.
[10] J. J. Roberts,et al. REPAIR OF cis -PLATINUM (II) DIAMMINE DICHLORIDE-INDUCED DNA DAMAGE AND CELL SENSITIVITY , 1980 .
[11] N. Kaibara,et al. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment , 2002, Apoptosis.
[12] A. Fersht,et al. Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.
[13] A. Grothey,et al. Cisplatin resistance and oncogenes - a review , 2000, Anti-cancer drugs.
[14] S. Crooke,et al. Cisplatin : current status and new developments , 1980 .
[15] L. Kèlland,et al. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. , 1995, Journal of medicinal chemistry.
[16] Z. Ronai,et al. p53-Mdm2--the affair that never ends. , 2002, Carcinogenesis.
[17] E. Yazlovitskaya,et al. Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines , 2000, Molecular carcinogenesis.
[18] M. Pera,et al. DNA as a Target for Anticancer Coordination Compounds , 1983 .
[19] C. Sorenson,et al. Mechanisms of Resistance to Platinum Drugs , 1988 .
[20] M. Cobb,et al. Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.
[21] G. Mills,et al. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] A. Godwin,et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[23] Stephen B. Howell. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.
[24] Dirk Bohmann,et al. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis , 1999, Oncogene.
[25] A. Eastman,et al. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). , 1988, Biochemistry.
[26] A. Eastman. Glutathione-mediated activation of anticancer platinum(IV) complexes. , 1987, Biochemical pharmacology.
[27] J. Harper,et al. Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.
[28] C. R. Pinkerton,et al. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance , 2001, British Journal of Cancer.
[29] M. Pincus,et al. MEKK1/JNK signaling stabilizes and activates p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] D. Meek,et al. Mechanisms of switching on p53: a role for covalent modification? , 1999, Oncogene.
[31] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[32] N. Holbrook,et al. Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.
[33] A. Eastman,et al. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. , 1989, Biochemistry.
[34] T. Rikiyama,et al. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. , 2002, Biochemical and biophysical research communications.
[35] K. Kinzler,et al. Sequence-specific transcriptional activation is essential for growth suppression by p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] N. Ibrahim,et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.
[37] Weiya Ma,et al. Requirement of ATM in UVA-induced Signaling and Apoptosis* , 2002, The Journal of Biological Chemistry.
[38] B. Koller,et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.
[39] Kathleen R. Cho,et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Cornelison,et al. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. , 1993, Carcinogenesis.
[41] T. Mak,et al. ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53* , 2002, The Journal of Biological Chemistry.
[42] C. Cordon-Cardo,et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. , 1995, The Journal of urology.
[43] L. Hartwell,et al. Cell cycle control and cancer. , 1994, Science.
[44] A. Eastman. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. , 1987, Pharmacology & therapeutics.
[45] Z. Oltvai,et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.
[46] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[47] Moshe Oren,et al. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis , 2002, Oncogene.
[48] S. Lippard. Platinum, gold, and other metal chemotherapeutic agents : chemistry and biochemistry , 1983 .
[49] John Calvin Reed,et al. Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.
[50] E. Yazlovitskaya,et al. Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin* , 2000, The Journal of Biological Chemistry.
[51] A. Eastman,et al. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.
[52] F. Zunino,et al. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells , 2001, Oncogene.
[53] V. Reuter,et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.
[54] P. Modrich,et al. Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.
[55] D. Crowther,et al. Metallothionein levels in ovarian tumours before and after chemotherapy. , 1991, British Journal of Cancer.
[56] S. Dooley,et al. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. , 1996, Biochemical and biophysical research communications.
[57] P. Beale,et al. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.
[58] M. Marinus,et al. MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.
[59] M. Kastan,et al. p53 and ATM: cell cycle, cell death, and cancer. , 1997, Advances in cancer research.
[60] P. Beale,et al. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma , 2000, British Journal of Cancer.
[61] J. Gutkind,et al. Regulation of p73 by c-Abl through the p38 MAP kinase pathway , 2002, Oncogene.
[62] Ericka Stricklin-Parker,et al. Ann , 2005 .
[63] R. Ozols. Ovarian cancer: new clinical approaches. , 1991, Cancer treatment reviews.
[64] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[65] H. Hollema,et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] S. Lippard,et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[67] Antonio Costanzo,et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.
[68] A. Khokhar,et al. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.
[69] P. O'Connor,et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.
[70] T. Jacks,et al. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.
[71] I. Pastan,et al. Decreased accumulation of [14c]carboplatin in human cisplatin‐resistant cells results from reduced energy‐dependent uptake , 2000, Journal of cellular physiology.
[72] E. Martín-Blanco. p38 MAPK signalling cascades: ancient roles and new functions , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[73] Lianfa Shi,et al. Premature p34cdc2 activation required for apoptosis. , 1994, Science.
[74] D. Lilley,et al. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[75] Cori Bargmann,et al. The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.
[76] N. Nomura,et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.
[77] E. Solary,et al. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.
[78] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[79] W. Earnshaw,et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. , 1997, Blood.
[80] H. Miyake,et al. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. , 1999, The Journal of urology.
[81] D. Hamer,et al. Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.
[82] S. Lippard,et al. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). , 1991, Biochemistry.
[83] S. Chaney,et al. Specificity of platinum-DNA adduct repair. , 1999, Journal of inorganic biochemistry.
[84] M. Oren,et al. Regulation of p53 , 2002, Annals of the New York Academy of Sciences.
[85] P. Beaune,et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] S. Chaney,et al. DNA repair: enzymatic mechanisms and relevance to drug response. , 1996, Journal of the National Cancer Institute.
[87] Y. Taya,et al. Cisplatinum and taxol induce different patterns of p53 phosphorylation. , 2001, Neoplasia.
[88] A. Fornace,et al. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. , 1997, Experimental cell research.
[89] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[90] M. Gore,et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. , 1989, British Journal of Cancer.
[91] S. Lippard,et al. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[92] A. Sancar. Mechanisms of DNA excision repair. , 1994, Science.
[93] S. Lippard,et al. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. , 1990, Biochemistry.
[94] S. Farrow,et al. New members of the Bcl-2 family and their protein partners. , 1996, Current opinion in genetics & development.
[95] L. Kèlland,et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.